Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark J Roschewski, M.D.
National Cancer Institute (NCI)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uc San Diego Moores Cancer Center
La Jolla, California, United States
- Ucla Center for Clinical Aids Research and Education
Los Angeles, California, United States
- Emory University /winship Cancer Institute
Atlanta, Georgia, United States
- University of Illinois
Chicago, Illinois, United States
- University of Iowa/holden Comprehensive Cancer Center
Iowa City, Iowa, United States
- University of Kentucky /markey Cancer Center
Lexington, Kentucky, United States
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- Massachusetts General Hospital Cancer Centers
Boston, Massachusetts, United States
- West Michigan Cancer Center
Kalamazoo, Michigan, United States
- Fairview - Southdale Hospital
Edina, Minnesota, United States
- Unity Hospital
Fridley, Minnesota, United States
- Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
- Mount Sinai Hospital
New York, New York, United States
- University of Rochester
Rochester, New York, United States
- Montefiore Medical Center - Moses Campus
The Bronx, New York, United States
- Vidant Oncology-Kinston
Kinston, North Carolina, United States
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
- Case Western Reserve University
Cleveland, Ohio, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- Metrohealth Medical Center
Cleveland, Ohio, United States
- University of Tennessee - Knoxville
Knoxville, Tennessee, United States
- Ut Southwestern /simmons Cancer Center- Dallas
Dallas, Texas, United States
- Md Anderson Cancer Center
Houston, Texas, United States
- University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
- Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 25 Mar 2010
- Primary completion
- 30 Sept 2020
- Completion
- 16 Feb 2023
- Last update posted
- 27 Apr 2023
- Registered enrollment
- 194
- Registry id
- NCT01092182
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.